PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Putz, Eva Maria ^a   Prchal Murphy, Michaela ^a   Simma, Olivia Annabella ^b   Forster, Florian ^c   Koenig, Xaver ^d   Stockinger, Hannes ^c   Piekorz, Roland P ^e   Freissmuth, Michael ^d   Müller, Mathias ^a   Sexl, Veronika ^a   Zebedin Brandl, Eva ^d  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b OSAKA UNIVERSITY   (Japan)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; CD69 ANTIGEN; DEATH RECEPTOR; GRANZYME; MESSENGER RNA; PERFORIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CARCINOMA CELL; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DISEASE SEVERITY; ELECTRIC CAPACITANCE; ENZYME INHIBITION; FASL GENE; GENE; GRZMA GENE; IMMUNOPHENOTYPING; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PFR1 GENE; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TRAIL GENE; TUMOR VOLUME;

ANIMALS; CALCIUM; CELL DEGRANULATION; CELL PROLIFERATION; CYTOPLASMIC GRANULES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; T-LYMPHOCYTES, CYTOTOXIC;

MUS;

EID: 84863764147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040852     Document Type: Article

References (53)

1. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18721898.
2. Fruman DA, Cantley LC, (2002) Phosphoinositide 3-kinase in immunological systems. Semin Immunol 14: 7-18 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11884226.
3. Beer-Hammer S, Zebedin E, von Holleben M, Alferink J, Reis B, et al. (2010) The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. Journal of leukocyte biology 87: 1083-1095. Available:http://www.ncbi.nlm.nih.gov/pubmed/20200404. Accessed 2011 July 27.
4. So L, Fruman DA, (2012) PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. The Biochemical journal 442: 465-481. Available:http://www.ncbi.nlm.nih.gov/pubmed/22364281. Accessed 2012 March 22.
5. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, et al. (2002) Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22: 8580-8591 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12446777.
6. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, et al. (2002) A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 196: 753-763. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12235209. Accessed 2011 Aug 11.
7. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, et al. (2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287: 1040-1046 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10669416.
8. Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, et al. (2007) Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 110: 2940-2947. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17626838. Accessed 2012 March 5.
9. Webb LM, Vigorito E, Wymann MP, Hirsch E, Turner M, (2005) Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 175: 2783-2787 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16116162.
10. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, et al. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12130661.
11. Garcon F, Patton DT, Emery JL, Hirsch E, Rottapel R, et al. (2008) CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood 111: 1464-1471 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18006698.
12. Okkenhaug K, Patton DT, Bilancio A, Garcon F, Rowan WC, et al. (2006) The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol 177: 5122-5128 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17015696.
13. Nashed BF, Zhang T, Al-Alwan M, Srinivasan G, Halayko AJ, et al. (2007) Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol 37: 416-424 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17236236.
14. Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, et al. (2011) PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. Journal of autoimmunity 36: 278-287. Available:http://www.ncbi.nlm.nih.gov/pubmed/21396797. Accessed 27 July 2011.
15. Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, et al. (2006) Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 177: 6598-6602 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17082571.
16. Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, et al. (2010) Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116: 2078-2088. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2951855&tool=pmcentrez&rendertype=abstract. Accessed 2011 July 15.
17. Burger JA, (2012) Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Current hematologic malignancy reports 7: 26-33. Available:http://www.ncbi.nlm.nih.gov/pubmed/22105489. Accessed 2012 April 10.
18. Ma S, Rosen ST, (2011) Signal transduction inhibitors in chronic lymphocytic leukemia. Current opinion in oncology 23: 601-608. Available:http://www.ncbi.nlm.nih.gov/pubmed/21892084. Accessed 2012 June 6.
19. Swat W, Montgrain V, Doggett TA, Douangpanya J, Puri K, et al. (2006) Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 107: 2415-2422 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16304053.
20. Betts MR, Koup RA, (2004) Detection of T-cell degranulation: CD107a and b. Methods Cell Biol 75: 497-512. Available:http://www.ncbi.nlm.nih.gov/pubmed/15603439. Accessed 2011 September 28.
21. Brose N, Rosenmund C, (2002) Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. Journal of cell science 115: 4399-4411. Available:http://www.ncbi.nlm.nih.gov/pubmed/12414987. Accessed 2011 August 12.
22. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, et al. (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156: 3678-3686 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8621902.
23. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, et al. (2011) A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117: 1565-1573 Available:http://www.ncbi.nlm.nih.gov/pubmed/21127177.
24. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, et al. (2011) Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism. Immunity 34: 224-236. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3052433&tool=pmcentrez&rendertype=abstract. Accessed 2011 February 8.
25. Ali K, Camps M, Pearce WP, Ji H, Ruckle T, et al. (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180: 2538-2544 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18250464.
26. Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, et al. (2008) Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood 112: 4655-4664 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18684865.
27. Kerr WG, Colucci F, (2011) Inositol phospholipid signaling and the biology of natural killer cells. Journal of innate immunity 3: 249-257. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3219442&tool=pmcentrez&rendertype=abstract. Accessed 2012 April 5.
28. Guo H, Samarakoon A, Vanhaesebroeck B, Malarkannan S, (2008) The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med 205: 2419-2435 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18809712.
29. Saudemont A, Okkenhaug K, Colucci F, (2007) p110delta is required for innate immunity to transplantable lymphomas. Biochem Soc Trans 35: 183-185 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17371233.
30. Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo TG, et al. (2007) p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity 27: 214-227. Available:http://www.ncbi.nlm.nih.gov/pubmed/17723215. Accessed 2012 March 10.
31. Kim N, Saudemont A, Webb L, Camps M, Ruckle T, et al. (2007) The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110: 3202-3208. Available:http://www.ncbi.nlm.nih.gov/pubmed/17644738. Accessed 2012 April 27.
32. Zebedin E, Sandtner W, Galler S, Szendroedi J, Just H, et al. (2004) Fiber type conversion alters inactivation of voltage-dependent sodium currents in murine C2C12 skeletal muscle cells. American journal of physiology Cell physiology 287: C270-80. Available:http://www.ncbi.nlm.nih.gov/pubmed/15044148. Accessed 2011 Aug 12.
33. Südhof TC, Rothman JE, (2009) Membrane fusion: grappling with SNARE and SM proteins. Science (New York, NY) 323: 474-477. Available:http://www.ncbi.nlm.nih.gov/pubmed/19164740. Accessed 2011 June 21.
34. Vicogne J, Vollenweider D, Smith JR, Huang P, Frohman MA, et al. (2006) Asymmetric phospholipid distribution drives in vitro reconstituted SNARE-dependent membrane fusion. Proceedings of the National Academy of Sciences of the United States of America 103: 14761-14766. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1595425&tool=pmcentrez&rendertype=abstract. Accessed 2011 October 13.
35. Low PC, Misaki R, Schroder K, Stanley AC, Sweet MJ, et al. (2010) Phosphoinositide 3-kinase δ regulates membrane fission of Golgi carriers for selective cytokine secretion. The Journal of Cell Biology 190: 1053-1065. Available:http://www.ncbi.nlm.nih.gov/pubmed/20837769. Accessed 2011 July 26.
36. Lindsey WB, Lowdell MW, Marti GE, Abbasi F, Zenger V, et al. (2007) CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. Cytotherapy 9: 123-132. Available:http://www.ncbi.nlm.nih.gov/pubmed/17453964. Accessed 2011 July 15.
37. Mora JR, von Andrian UH, (2006) T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 27: 235-243 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16580261.
38. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, et al. (2008) Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 9: 513-521 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18391955.
39. Liu D, Uzonna JE, (2010) The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets. J Immunol 184: 3098-3105 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20154209.
40. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, et al. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95: 7556-7561 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9636188.
41. Soond DR, Bjørgo E, Moltu K, Dale VQ, Patton DT, et al. (2010) PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203-2213. Available:http://www.ncbi.nlm.nih.gov/pubmed/20081091. Accessed 2011 June 17.
42. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, et al. (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106: 1063-1066. Available:http://www.ncbi.nlm.nih.gov/pubmed/15840695. Accessed 2011 July 12.
43. Kong D, Yamori T, (2008) Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer science 99: 1734-1740. Available:http://www.ncbi.nlm.nih.gov/pubmed/18616528. Accessed 2011 July 4.
44. Castillo JJ, Furman M, Winer ES, (2011) CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert opinion on investigational drugs. Available:http://www.ncbi.nlm.nih.gov/pubmed/22112004. Accessed 2011 Dec 19.
45. Collins I, (2009) Targeted small-molecule inhibitors of protein kinase B as anticancer agents. Anti-cancer agents in medicinal chemistry 9: 32-50. Available:http://www.ncbi.nlm.nih.gov/pubmed/19149480. Accessed 2011 July 15.
46. McHardy T, Caldwell JJ, Cheung K-M, Hunter LJ, Taylor K, et al. (2010) Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). Journal of medicinal chemistry 53: 2239-2249. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2832868&tool=pmcentrez&rendertype=abstract. Accessed 2011 July 15.
47. Gadgil A, Duncan SR, (2008) Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease 3: 531-541. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2650590&tool=pmcentrez&rendertype=abstract. Accessed 2011 Dec 19.
48. Ying H, Fu H, Rose ML, McCormack AM, Sarathchandra P, et al. (2012) Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts. PloS one 7: e32892. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3316549&tool=pmcentrez&rendertype=abstract. Accessed 2012 April 26.
49. Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, et al. (2009) Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res 69: 203-211 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19118004.
50. Hickey FB, Cotter TG, (2006) BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. The Journal of biological chemistry 281: 2441-2450. Available:http://www.ncbi.nlm.nih.gov/pubmed/16291747. Accessed 2012 April 25.
51. Lindau M, Neher E, (1988) Patch-clamp techniques for time-resolved capacitance measurements in single cells. Pflügers Archiv?: European journal of physiology 411: 137-146. Available:http://www.ncbi.nlm.nih.gov/pubmed/3357753. Accessed 2011 Aug 29.
52. Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, et al. (2006) IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24: 5461-5472 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16678312.
53. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, et al. (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2: 98-110 Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20201032. Accessed 2011 Nov 26.